Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses

(2015) Robert Howard et al.   LANCET NEUROLOGY

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model.

(2014) M Bond et al.   HEALTH TECHNOLOGY ASSESSMENT

Dementia care costs and outcomes: a systematic review

(2012) Martin Knapp et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determining the minimum clinically important differences for outcomes in the DOMINO trial

(2010) Robert Howard et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT

(2009) Rob Jones et al.   Trials

Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

(2008) Anton Porsteinsson et al.   Current Alzheimer Research